Alain H.
- Country
- France
- Department
- Service de dermatologie
Research Overview
- Phase 1a/1b Evaluation of KM-023 in Healthy Volunteers and Patients with Olmsted Syndrome
- A double-blind, randomized, placebo-controlled, interventional, multicenter, phase III clinical trial to investigate the safety and efficacy of ABCB5-positive mesenchymal stromal cells (ABCB5+ MSCs) on epidermolysis bullosa (EB)
- Evaluation of Safety and Efficacy of Topical SXR1096 Cream in Patients with Netherton Syndrome: A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 8 of 39 partner sites.
Specializations
Rare Skin Disorders
This investigator specializes in treating severe genetic skin conditions, with particular focus on Netherton Syndrome, a rare inherited disorder affecting skin barrier function and immunity.
- Novel therapeutic approaches for Netherton Syndrome
- Topical treatment development
- Immunological interventions
The research encompasses both systemic and topical treatment modalities for managing skin barrier dysfunction.
Genetic Skin Diseases
Specialized expertise in Epidermolysis Bullosa, focusing on both recessive dystrophic (RDEB) and junctional (JEB) variants of this genetic condition.
- Cell-based therapies
- Gene therapy applications
- Regenerative medicine approaches
The work involves advanced therapeutic strategies including cellular and molecular interventions.
Therapeutic Innovation
Advancing treatment options through experimental medicine and pioneering therapeutic approaches for rare dermatological conditions.
- First-in-human studies
- Biological therapy development
- Autologous skin grafting techniques
Research focuses on translating laboratory discoveries into clinical applications for severe genetic skin disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.